July 25th, Science and Technology Department of Xinjiang branch surveyed Hua Shi Dan Pharmaceutical Research Co., Ltd and conducted a site inspection for the project Research on Antitumor Mechanism of the β-Carboline Derivative HMD.
In 2010, based on medicine evaluation studies on the antitumor drug HMD, Xinjiang Hua Shi Dan Pharmaceutical Research Co., Ltd and the Institute of Biophysics of Chinese Academy of Sciences conducted a joint study on its anti-tumor mechanism with the support of Sci-Tech programs funded for Xinjiang. Currently, the project has successfully completed the expected target and clearly demonstrated the molecular mechanism of the anti-tumor effect of β-carboline derivative HMD, and got 6 domestic invention patents and an international invention patent. Besides, 1 relevant thesis was published in SCI.
According to the responsible person of the company, the development of anti-cancer drugs with independent intellectual property is one strategic direction of Hua Shi Dan medicine company. With the completion of the project, HMD drugs for clinical research have been laid the foundation and the development of Xinjiang ethnic medicine will be greatly promoted.